<DOC>
	<DOCNO>NCT00002085</DOCNO>
	<brief_summary>To evaluate efficacy safety azithromycin give chronically treatment serious nontuberculous mycobacterial infection patient fail intolerant available therapy .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Azithromycin Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing Intolerant Other Available Therapy</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Other antimicrobial drug long document Case Report Form . Patients must : Serious nontuberculous mycobacterial infection . Approval eligibility Pfizer Clinical Monitor . Patients legal age consent must consent parent guardian . NOTE : Pregnant woman , woman childbearing potential , child specifically exclude participation . However , patient physician aware safety azithromycin pregnancy longterm use child adult establish . The risk benefit azithromycin use patient consider consultation physician Pfizer Clinical Monitor . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Disseminated Mycobacterium avium complex ( MAC ) eligible treatment azithromycin protocol 066162 . Known hypersensitivity intolerance macrolide antibiotic . Patients follow prior condition exclude : History hypersensitivity intolerance azithromycin .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1998</verification_date>
	<keyword>Mycobacterium avium-intracellulare Infection</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Azithromycin</keyword>
	<keyword>Mycobacterium Infections , Atypical</keyword>
</DOC>